INTRODUCTION {#h0.0}
============

Influenza A viruses are the causative agents of annual epidemics of respiratory disease and occasionally generate pandemics with variable consequences for human health and the global economy ([@B1]). The 1918 pandemic caused some 50 million deaths ([@B2]), while the last pandemic, in 2009, was much milder and a normal yearly epidemic causes up to 500,000 deaths worldwide (<http://www.who.int/mediacentre/factsheets/fs211/en/>).

The genome of influenza A viruses is a set of eight single-stranded, negative-polarity RNAs that are assembled in ribonucleoprotein complexes (RNPs) and incorporated into enveloped particles ([@B3]). Upon entry into the infected cell, viral RNPs are imported into the nucleus, where viral transcription and replication take place. The first step in virus gene expression is transcription from the parental RNPs, and translation of these early viral mRNAs is essential for viral RNP replication ([@B4]). At least the virus nucleoprotein (NP) and polymerase (PB1, PB2, and PA proteins) are necessary to produce progeny RNPs ([@B5]). This process involves first the generation of complementary RNPs that serve as efficient templates for the production of large amounts of progeny RNPs (reviewed in references [@B6] to [@B9]). Progeny RNPs are then exported back to the cytoplasm and bud from the cell membrane (reviewed in reference [@B10]).

At present, two types of anti-influenza virus drugs are available, the adamantanes, which block the M2 ion channel, and the neuraminidase inhibitors, which interfere with virion release (reviewed in reference [@B11]), as well as the polymerase inhibitor favipiravir (T-705) ([@B12]), which has been recently approved in Japan. In addition, a number of other compounds have been described that are specific for targets related to virus transcription/replication and may become useful in the clinic in the future ([@B13][@B14][@B21]) and others have been reported to inhibit virus-induced membrane fusion (reviewed in reference [@B22]). However, a common problem for the virus target-directed antivirals is the generation of resistant virus strains. Most circulating influenza viruses are resistant to adamantanes, and virus strains resistant to neuraminidase inhibitors have been described upon clinical use ([@B23]) or independently of drug use ([@B24]). Likewise, some of the potential new inhibitors have been shown to readily select for resistant mutants ([@B16], [@B21]). Hence, a large effort has been made to identify cellular targets that could be useful in indirectly reducing influenza virus multiplication and/or pathogenesis.

Early efforts in this direction came from the observation that some signaling pathways are altered during influenza virus infection ([@B25][@B26][@B29]), and modulation of influenza virus multiplication was attempted with drugs designed to alter cell signaling (reviewed in references [@B30] and [@B31]). These approaches reflect the general requirement of cellular pathways and biosynthetic machineries for virus multiplication that has been the subject of much attention in recent years. Thus, the identification of cellular factors important for influenza virus replication has been addressed by a number of different approaches, like targeted ([@B32][@B33][@B34]) or general ([@B35]) two-hybrid screens, as well as targeted proteomic analyses of virus-containing intracellular complexes ([@B36], [@B37]) or purified virions ([@B38], [@B39]). In addition, genome-wide downregulation of cellular gene expression has identified a plethora of genes that can alter influenza virus multiplication ([@B35], [@B40][@B41][@B43]; reviewed in reference [@B44]). This information has been complemented with general analyses of the alterations in cellular gene expression induced by influenza virus infection, at either the RNA ([@B45][@B46][@B47]) or the protein ([@B48], [@B49]) level. Knowledge derived from these virus-host interaction studies has fostered the search for inhibitors targeted to cellular factors that may serve as influenza antivirals (reviewed in references 50 to 53).

Here we have taken an alternative approach to identify potential cellular targets for anti-influenza virus intervention. By screening collections of drugs approved for human use in a green fluorescent protein (GFP)-based virus transcription-replication system, we identified Montelukast (MK) as an inhibitor of virus gene expression and validated these results in virus-infected cells. The selectivity index of MK was rather low, and hence, it is not a potential antiviral *per se*, but we used it as a probe to identify the cellular target affected. By deep sequencing of RNA isolated from mock- and virus-infected human cells, treated with MK or left untreated, we showed that it counteracts the influenza virus-induced block in the PERK-mediated unfolded protein stress response. In agreement with these alterations in cellular gene expression, PERK phosphorylation was inhibited in infected cells but stimulated in MK-treated cells, and accordingly, inhibition of PERK phosphorylation led to increased viral gene expression. These results suggest the PERK-mediated unfolded protein response as a potential cellular target to modulate influenza virus infection.

RESULTS AND DISCUSSION {#h1}
======================

Screening of clinically tested human drugs for influenza virus inhibition in a GFP-based replicon assay. {#s1.1}
--------------------------------------------------------------------------------------------------------

With the aim to identify new cellular targets for influenza virus inhibition, we reasoned that screening with a recombinant replicon system would address an early step in the virus replication cycle, namely, virus transcription/replication and/or gene expression, and hence provide a stage of virus infection more useful for inhibition. In addition, we reasoned that by using a restricted library of compounds that have been approved as drugs for human use would most probably ensure that a cellular target would be addressed.

To set up a screening platform, we adapted our previous know-how with viral replicon systems expressing chloramphenicol acetyltransferase to use a more versatile GFP marker. Recombinant RNPs containing the GFP-encoding gene in negative polarity were generated by transfection of viral RNA polymerase, NP, and genomic plasmids into human HEK293T cells as previously described ([@B54]). As a negative control, RNPs were prepared from which the plasmid encoding the PB1 subunit of the polymerase was omitted. In addition, we downscaled it to a 96-well plate format to carry out medium-throughput screening. After optimizing the transfection parameters and replication time, we could observe reproducible GFP expression in most of the cells in each culture ([Fig. 1A](#fig1){ref-type="fig"}, DMSO \[dimethyl sulfoxide\]) and a very low background fluorescence level in the negative-control cultures ([Fig. 1A](#fig1){ref-type="fig"}, CTRL). To determine the quality of the screening system, multiple transfected cultures were analyzed for fluorescence signal, standard deviation, reproducibility factor, coefficient of variation, and signal-to-noise and signal-to-background ratios ([@B55]). The results are shown in [Fig. S1](#figS1){ref-type="supplementary-material"} in the supplemental material, and the Z factor obtained indicates that the screening system developed is a fully suited assay. As a positive control for the inhibition of reporter expression, we used favipiravir (T-705), a well-known inhibitor of virus RNA replication ([@B12]). As presented in [Fig. 1A](#fig1){ref-type="fig"} (T-705) and quantitated in [Fig. 1B](#fig1){ref-type="fig"}, statistically significant inhibition was observed upon the addition of favipiravir 2 h after transfection (*P* \< 0.0001, as determined by the Student *t* test).

![Recombinant GFP-based screening for influenza virus inhibitors. Cultures of human HEK293T cells in 96-well plates were used to reconstitute a GFP minireplicon system and treated with vehicle (DMSO) or favipiravir (T-705). As a control, similar experiments were performed without the PB1 subunit of the viral polymerase (CTRL). (A) Fluorescence images. (B) GFP fluorescence values of DMSO-treated wells (blue), T-705-treated wells (gray), and individual wells treated with specific compounds from the NIH library (green). The blue and gray horizontal bars indicate the averages of DMSO- or T-705-treated wells, and the corresponding shadowed zones indicate the standard deviations. Specific compounds that are potentially toxic (stars) or inhibitors of GFP expression (triangles) were identified. AU, arbitrary units. (C) Overview of the screening process. Out of 727 specific compounds from the NIH libraries, 495 did not alter the GFP signal, 36 compounds increased the GFP signal, and 196 decreased the GFP signal. These 196 compounds were used for counterscreening for toxicity and specificity. Cultures of human HEK293T cells in 96-well plates were transfected with plasmid pCAGGsGFP or used to reconstitute RNP-GFP and treated individually with the 196 candidate compounds. Fourteen compounds showed no toxicity, and 16 were partly toxic and were tested at lower concentrations. Finally, 22 compounds decreased the GFP signal in the context of the replicon system (RNP-GFP) but not in the context of an RNA polymerase II-dependent system (pCAGGsGFP). These 22 compounds were used for inhibition of infection of A549 and Huh7 cells with the VIC and WSN strains. Only ribavirin, a known inhibitor of influenza virus infection, and MK reduced virus yields under all of the conditions analyzed.](mbo0021627760001){#fig1}

We then used NIH libraries of approved drugs, including a total of 727 compounds, to perform screening in the system, always including negative (DMSO) and positive (T-705) controls in the same plate. We chose a dose of 50 µM for the first screening, as pilot tests indicated that less than 10% of the compounds led to toxicity or inhibition. A sample of the results obtained is presented in [Fig. 1B](#fig1){ref-type="fig"}. Most of the compounds were not active, but some of them abolished GFP expression ([Fig. 1B](#fig1){ref-type="fig"}, stars). Another group of compounds (*n* = 196) reduced GFP to levels similar to those obtained with T-705 ([Fig. 1B](#fig1){ref-type="fig"}, arrowheads) and were selected for further analyses ([Fig. 1C](#fig1){ref-type="fig"}). To verify their activity and rule out unspecific or toxic compounds, the screening was repeated with both the indicated GFP-based replicon system and a control system in which GFP expression was driven by a polymerase II promoter (i.e., was independent of any virus element). The compounds that showed potential toxicity (i.e., induced aberrant cell morphology or reduced the cellular mass of the cultures) were further tested at lower concentrations (3, 6, 12, and 25 µM). In this way, 22 compounds were selected that showed activity in the GFP-based replicon system but did not inhibit cellular GFP expression ([Fig. 1C](#fig1){ref-type="fig"}). Finally, these 22 compounds were tested for inhibition of virus replication in low-multiplicity infections with the VIC (H3N2) and WSN (H1N1) strains of influenza virus in two human cell lines, A549 and Huh7, of epithelial and hepatic origins, respectively. Two compounds were found to reproducibly reduce virus yields: ribavirin, a known wide-range virus inhibitor ([@B56]), and MK sodium (see [Fig. S2A](#figS2){ref-type="supplementary-material"} in the supplemental material). To verify that MK was indeed able to reduce virus titers, the compound was purchased from a different provider, the identities of both the NIH Collection and the alternative compound were verified by mass spectrometry (see [Fig. S2B](#figS2){ref-type="supplementary-material"} and [C](#figS2){ref-type="supplementary-material"}) and the inhibition of virus multiplication was again verified by low-multiplicity infections as described above.

To evaluate the toxicity and effectiveness of MK, cultures of A549 human cells were treated with a range of compound concentrations and cell viability was determined by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay 48 h later. The results are presented in [Fig. 2A](#fig2){ref-type="fig"} and indicated a 50% cytotoxic concentration (CC~50~) of 52 ± 2 µM. Parallel cultures were treated under the same conditions and infected with the VIC influenza virus strain at 0.001 PFU/cell. At 48 h postinfection (hpi), virus titers in the supernatants were determined by plaque assay in MDCK cells. The results are presented in [Fig. 2B](#fig2){ref-type="fig"} and indicated a 50% inhibitory concentration (IC~50~) of around 26 µM. It is important to mention that virus production in the presence of 40 µM MK was below the limit of detection ([Fig. 2B](#fig2){ref-type="fig"}), in spite of only a marginal reduction in cell viability ([Fig. 2A](#fig2){ref-type="fig"}). To verify these results, cultures of A549 human cells were infected with the VIC influenza virus strain at 3 PFU/cell and treated with various MK concentrations and total cell extracts were prepared at 6 hpi. Under these conditions, no apparent cytotoxic effect on mock-infected cells was observed at any of the MK concentration used (data not shown) but the accumulation of viral NP showed a progressive decline, as determined by Western blotting, with an estimated IC~50~ of around 25 µM ([Fig. 2C](#fig2){ref-type="fig"}). These results indicate that MK is able to reduce influenza virus yields and reduces viral gene expression at nontoxic concentrations, in good agreement with the design of the screening procedure used, but indicates a selectivity index of around 2. Such a low selectivity index precludes the use of MK as a potential influenza virus inhibitor but still allows further studies to identify the target affected.

![Efficacy and toxicity of MK during influenza virus infection. (A) Cultures of human A549 cells were treated with the concentrations of MK indicated, and the mitochondrial activity of the cells was measured at 48 hpi with the MTT assay. (B) Cultures of human A549 cells were infected with the VIC virus strain at an MOI of 0.001 PFU/cell and treated with the concentrations of MK indicated. Virus titration was performed with samples obtained at 48 hpi. (C) Cultures of human A549 cells were infected with VIC at an MOI of 3 PFU/cell and treated with the concentrations of MK indicated. At 6 hpi, the accumulation of NP and β-actin was determined by Western blotting with specific antibodies. The quantification of the NP signal is represented at the bottom. The data in panels A and B are presented as averages and standard deviations of three independent biological replicates.](mbo0021627760002){#fig2}

MK preferentially inhibits viral protein synthesis. {#s1.2}
---------------------------------------------------

To determine whether the reduction of virus protein accumulation observed under treatment with MK was due to an inhibition of virus transcription/replication or viral protein synthesis, we first measured the *in vitro* activity of recombinant RNPs treated with MK or left untreated. Recombinant mini-RNPs containing a 248-nucleotide (nt)-long template (clone 23 RNPs) were generated by transfection of viral polymerase, NP, and genomic plasmids into human HEK293T cells as previously described ([@B57]). As a negative control, parallel transfections were carried out in which the plasmid encoding the PB1 subunit of the polymerase was omitted. The RNA synthesis capacity of total cell extracts was determined in the presence of 20 µM MK or the corresponding amount of vehicle (DMSO) by quantification of the transcript generated, after separation by denaturing gel electrophoresis. An example of the results is presented in [Fig. 3A](#fig3){ref-type="fig"}, and the quantitative data of several replicate experiments are shown in [Fig. 3B](#fig3){ref-type="fig"}. These results indicate that MK does not alter viral RNA synthesis *in vitro*. To analyze viral RNA synthesis during infection, we carried out deep sequencing of virus-specific RNAs present in mock- or virus-infected human cells treated with MK or left untreated. We chose 6 hpi as the time point because viral transcription and replication are well under way in cells infected at a high multiplicity (3 PFU/cell) and a 20 µM concentration of MK because it is not toxic to the cells and leads to partial viral protein synthesis inhibition (see [Fig. 4](#fig4){ref-type="fig"}). Duplicate biological replicates were subjected to Illumina sequencing after removal of rRNA. Analysis of the virus RNA sequences obtained verified that treatment with MK does not alter the accumulation of positive-polarity or negative-polarity viral RNAs during infection ([Fig. 3C](#fig3){ref-type="fig"} and [D](#figS3){ref-type="supplementary-material"}) and also indicated that the virus splicing process is unaltered by MK, since the M1/M2 and NS1/NEP mRNA ratios are indistinguishable under both experimental conditions (see [Fig. S3](#figS3){ref-type="supplementary-material"} in the supplemental material). To further verify whether viral transcription is altered by MK treatment, the accumulation of primary transcripts was determined by RT-qPCR of total cell RNA isolated from cells infected in the presence of cycloheximide, treated with MK or left untreated. The results are presented in [Fig. 3E](#fig3){ref-type="fig"} and confirm that MK does not affect influenza virus transcription.

![MK treatment does not alter influenza virus RNA synthesis. (A) Cultures of human HEK293T cells were transfected with plasmids expressing the polymerase subunits and the NP, as well as with a genomic plasmid expressing a deleted NS RNA segment (clone 23) ([@B57]) in negative polarity. As a control, similar experiments were performed without the PB1 subunit of the viral polymerase (CTRL). Extracts of these cultures were used for *in vitro* transcription with β-globin mRNA as a cap donor and 20 µM MK or the corresponding amount of DMSO. The transcripts were analyzed by denaturing polyacrylamide gel electrophoresis. The mobility of a genome-size marker of 248 nt is indicated to the left. (B) Quantification of the results in panel A as percentages of the transcriptional activity of RNPs treated with DMSO. Average values and standard deviation of three independent experiments are presented. (C, D) Cultures of human A549 cells were infected with influenza virus at an MOI of 3 PFU/cell and then treated with 20 µM MK or the corresponding amount of DMSO. Total cell RNA was isolated at 6 hpi, and rRNA was removed. Viral RNA of each segment was determined by deep sequencing and classified according to the virus segment and polarity. The results were standardized by the total number of reads per sample. The use of total histone mRNA reads for standardization led to similar results. (C) Total accumulation of positive-polarity RNA of each viral segment. (D) Total accumulation of negative-polarity RNA of each viral segment. The data in panels C and D are presented as averages and standard deviations of three independent biological replicates. (E) Cultures of human A549 cells were infected with influenza virus at an MOI of 3 PFU/cell and then treated with 20 µM MK or the corresponding amount of DMSO in the presence or absence of cycloheximide (100 µg/ml). Total cell RNA was isolated at 6 hpi, and the accumulation of viral RNA was determined by RT-qPCR with probes specific for the NP segment. The accumulation of viral mRNA in cells treated with cycloheximide (CHX) and/or MK or not treated is presented as the average and standard deviation of three determinations.](mbo0021627760003){#fig3}

![MK treatment preferentially inhibits influenza virus-specific protein synthesis. Cultures of human A549 cells were infected with influenza virus strain VIC (FLU) at an MOI of 1 to 3 PFU/cell and treated with the concentrations of MK (A and B), GSK-2656157 (GSK) (C, D), or guanabenz (GNZ) (E and F) indicated. At 6 hpi, the cultures were pulse-labeled with \[^35^S\]methionine-cysteine and total protein extracts were prepared. The samples were analyzed by polyacrylamide gel electrophoresis and autoradiography. (A, C, E) Autoradiographs of polyacrylamide electrophoresis gels from representative experiments are presented. The mobility of some of the virus-specific proteins is indicated to the right. (B, D, F) Quantification of the signals of cellular proteins (red) and viral proteins (gray) at the MK, GSK, or GNZ concentrations indicated. The average and standard deviation of three independent experiments are presented. Significance of treated-infected versus nontreated-infected cells (black stars) or mock-infected versus infected cells (gray stars) was determined by the Student *t* test (\*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001).](mbo0021627760004){#fig4}

Next, we determined the effect of MK on the protein synthesis activity in mock- or virus-infected cells. Cultures of A549 cells were infected at 3 PFU/cell or mock infected and treated with various amounts of MK. At 6 hpi, the cells were labeled with \[^35^S\]methionine-cysteine for 1 h and total cell extracts were prepared and analyzed by denaturing gel electrophoresis and autoradiography. The results of a representative experiment are shown in [Fig. 4A](#fig4){ref-type="fig"} and indicate partial inhibition of viral protein synthesis at 20 µM MK and almost complete inhibition at 40 µM. In contrast, cellular protein synthesis was almost unaltered at 20 µM MK and only marginally affected at 40 µM MK. These data result in a CC~50~ of about 62 µM and an IC~50~ of around 24 µM ([Fig. 4B](#fig4){ref-type="fig"}), in good agreement with previous results ([Fig. 2](#fig2){ref-type="fig"}), and suggest that viral protein synthesis is the target of MK action during infection, although nucleocytoplasmic mRNA transport could not be excluded at this point (but see below).

MK stimulates the PERK-dependent pathway of the unfolded protein response. {#s1.3}
--------------------------------------------------------------------------

As neither *in vitro* transcription of viral RNPs nor accumulation of viral RNAs in infected cells was altered by MK addition ([Fig. 3](#fig3){ref-type="fig"}), we assumed that the target of MK anti-influenza virus activity is cellular. To identify such a potential cellular target, we carried out deep-sequencing analysis of the cellular RNAs present in mock- or virus-infected human cells treated with MK or left untreated. Duplicate cultures of A549 cells were infected at 3 PFU/cell or mock infected and treated with 20 µM MK, a dose that neither affected cell viability ([Fig. 2A](#fig2){ref-type="fig"}) nor reduced cellular protein synthesis ([Fig. 4A](#fig4){ref-type="fig"}), or left untreated. Deep-sequencing analysis was started by comparing the expression of cellular RNAs in virus-infected cells treated with MK or left untreated. When a false-discovery rate (FDR) of \<10^−3^ was used as a statistical significance cutoff, a number of cellular genes were overexpressed in virus-infected cells upon MK treatment with changes ranging from 1.87- to 6.2-fold ([Fig. 5A](#fig5){ref-type="fig"}, left side, red dots, and B). The potential interactions between the cellular genes identified in [Fig. 5](#fig5){ref-type="fig"} were tested by using the STRING database, and several of them (ATF4, TRIB3, DDIT4, and ASNS) appeared to be connected in an interaction network, based on experimental, text mining, and database searching evidence (see [Fig. S4](#figS4){ref-type="supplementary-material"} in the supplemental material, where they are circled in red), and they all represent genes downstream of the PERK-mediated arm of the unfolded protein stress response (UPR) ([@B58], [@B59]). To verify that the ATF6 and IRE1 arms of the UPR were also induced by MK treatment, the RNA accumulation of a number of their downstream genes was checked and none was upregulated in virus-infected cells upon MK treatment (see [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material; FLU-MK versus FLU). Thus, it could be concluded that MK specifically stimulates the PERK arm of the UPR during virus infection.

![The PERK-dependent unfolded protein response pathway is differentially altered by influenza virus infection or MK treatment. Cultures of A549 cells were infected with influenza virus at an MOI of 3 (FLU) or mock infected (MOCK) and treated with 20 µM MK or not treated. At 6 hpi, total nonribosomal RNA was subjected to RNA-Seq analysis. The results were standardized by the total number of reads per sample. The use of total histone mRNA reads for standardization led to similar results. (A) FIESTA diagrams ([@B97]) indicating the number of differentially expressed human genes across the comparison of MK-treated versus DMSO-treated infected cells (left side), MK-treated versus untreated mock-infected cells (middle), and infected versus mock-infected cells (right side). On the left side, the genes with an FDR of \<10^−3^ and an FC of \>1.7 are shown with red dots. The yellow dot corresponds to a pseudogene with an FDR of \>5.10^−3^. The position of this set of genes in the other comparisons is marked in red (middle) or green (right side). (B) Table with the products of the genes marked with red dots on the left side of panel A. The FC and FDR are presented for each of the comparisons shown in panel A. (C) The accumulation of RNA for the genes listed in panel B, obtained from DMSO-treated (blue), MK-treated (red), mock-infected (−), or influenza virus-infected (+) cells by deep sequencing, is shown (number of reads standardized as in [Fig. 3D](#fig3){ref-type="fig"}). The data are presented as the average and range of two independent biological replicates.](mbo0021627760005){#fig5}

When the gene set described in [Fig. 5B](#fig5){ref-type="fig"} was considered in the two alternative comparisons included in the experimental setting, it became clear that they were all overexpressed upon MK treatment of mock-infected cells ([Fig. 5A](#fig5){ref-type="fig"}, middle, red dots, and B) and they were all downregulated in virus-infected versus mock-infected cells, albeit to a lesser extent ([Fig. 5A](#fig5){ref-type="fig"}, right side, green dots, and B). For a direct comparison, these data are jointly represented in [Fig. 5C](#fig5){ref-type="fig"} and all together indicate that MK treatment is able to restore the expression of this set of genes to the normal levels observed in untreated cells. To test whether MK treatment counteracts the downregulation of any gene as a consequence of virus infection, we selected those showing a fold change (FC) of less than −3 and an FDR of \<10^−3^. The alterations of the 15 genes identified upon MK treatment were analyzed, and the results indicate that MK treatment does not unspecifically counteract cellular genes downregulated by virus infection (see [Table S2](#tabS2){ref-type="supplementary-material"} in the supplemental material).

MK induces PERK phosphorylation and counteracts the influenza virus-induced block of the PERK pathway. {#s1.4}
------------------------------------------------------------------------------------------------------

The first step in the induction of the PERK-dependent UPR is the dimerization and autophosphorylation of PERK ([Fig. 6A](#fig6){ref-type="fig"}), and the transcriptomic analysis shown above suggests that MK treatment stimulates PERK phosphorylation. To directly evaluate this possibility, we measured the amounts of P-PERK and total PERK in mock-infected and influenza virus-infected A549 cell cultures treated with various MK concentrations. As a control for PERK phosphorylation, the cultures were treated with thapsigargin, a well-known UPR stimulator ([@B60]), and a clear increase in the levels of P-PERK was observed in both mock- and virus-infected cells ([Fig. 6B](#fig6){ref-type="fig"}, C+). Treatment of normal cells with MK progressively induced PERK phosphorylation ([Fig. 6B](#fig6){ref-type="fig"}, MOCK), while virus infection reduced the P-PERK levels ([Fig. 6B](#fig6){ref-type="fig"}, compare FLU with MOCK, untreated). Treatment of virus-infected cells with MK led to the restoration of P-PERK levels to those found in normal cells ([Fig. 6B](#fig6){ref-type="fig"}, compare lanes MOCK 0 and FLU 40). In agreement with the results shown in [Fig. 2C](#fig2){ref-type="fig"}, the NP accumulation was strongly reduced upon treatment with MK at 40 µM and, interestingly, it was also reduced upon treatment with thapsigargin ([Fig. 6](#fig6){ref-type="fig"}, NP, C+). The quantitation of several experiments similar to that presented in [Fig. 6B](#fig6){ref-type="fig"} is presented in [Fig. 6C](#fig6){ref-type="fig"} and indicates an opposite and statistically significant variation of PERK phosphorylation by virus infection and by MK treatment.

![MK treatment reverses influenza virus-induced PERK dephosphorylation. (A) Scheme of pathways activated by accumulation of unfolded or misfolded proteins in the lumen of the endoplasmic reticulum. The pathways activated by ATF6, PERK, and IRE1 are indicated. Most relevant for this study, the PERK-dependent pathway is highlighted, including the eiF2α-dependent translation block and the downstream genes identified here as upregulated by MK treatment in virus-infected cells. (B) Cultures of human A549 cells were infected with VIC virus at an MOI of 3 PFU/cell (FLU) or mock-infected (MOCK) and treated with 20 or 40 µM MK or 1 mM of thapsigargin (C+). At 6 hpi, the accumulation of P-PERK, total PERK, NP, and β-actin was determined by Western blotting with specific antibodies. (C) The quantification of the P-PERK signal is presented as the average and standard deviation of five determinations. Significance of differences between treated cells and untreated mock-infected cells (black stars), between treated and untreated virus-infected cells (red stars), and between infected cells and mock-infected cells without treatment (blue stars) was determined by the Student *t* test (\*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001).](mbo0021627760006){#fig6}

Virus infection is among the various stimuli that induce the UPR, probably because of the rapid demand of protein synthesis and folding capacity made by the virus. Some viruses, like hepatitis C virus and many other positive-polarity RNA viruses, have evolved not only to resist the UPR but also to take advantage of it (reviewed in references [@B61] and [@B62]), much in the same way that influenza viruses have usurped other signaling pathways to optimize the replication cycle (see below). However, firing of the PERK-mediated UPR leads to protein synthesis attenuation by phosphorylation of the eIF2α translation factor and hence constitutes a strong limitation of the rapid demand exerted by acute influenza virus infection. To test whether other fast-replication viruses are inhibited by MK, we carried out experiments similar to that presented in [Fig. 4](#fig4){ref-type="fig"} with the New Caledonia (H1N1) strain of influenza virus and vesicular stomatitis virus (VSV). Results showed that the protein synthesis of both viruses was strongly reduced under conditions that did not alter cellular protein synthesis (see [Fig. S5](#figS5){ref-type="supplementary-material"} in the supplemental material). This observation is in agreement with protein translation being the crucial step in MK-induced virus inhibition, as VSV is a cytoplasmic negative-stranded RNA virus with no nuclear phase.

It is no surprise that, acting as an inducer of PERK phosphorylation ([Fig. 6](#fig6){ref-type="fig"}), MK showed up as an inhibitor in the screening based on virus RNP-based GFP expression ([Fig. 1](#fig1){ref-type="fig"}), led to preferential reduction of viral protein synthesis, and inhibited virus multiplication in cultured cells ([Fig. 2](#fig2){ref-type="fig"} and [4](#fig4){ref-type="fig"}). Consistent with these findings, treatment of influenza virus-infected cells with GSK-2656157, a specific inhibitor of PERK phosphorylation, led to a dose-dependent increase in viral protein synthesis ([Fig. 4C](#fig4){ref-type="fig"} and [D](#fig4){ref-type="fig"}). Although the rather low CC~50~-to-IC~50~ ratio observed ([Fig. 3](#fig3){ref-type="fig"} and [5](#fig5){ref-type="fig"}) precluded any use of MK as an influenza virus inhibitor, the results presented support the use of PERK phosphorylation as a target to limit virus multiplication. Being a cellular target, it would have a low probability of eliciting the appearance of resistant virus strains and could be considered complementary to those virus targets already shown to be effective or in the process of development. Conversely, alterations of the PERK-dependent UPR might lead to potential deregulation of other stress response pathways that may have side effects on the host cell. However, since influenza virus infection produces an acute disease that would require only short-term treatment, the consequences of these potential side effects might be less relevant. Although inhibition of other cell signaling pathways has been extensively considered for anti-influenza virus treatment (reviewed in reference 31), the PERK-driven UPR has not been described yet as a potential influenza virus target. However, inhibitors of eIF2α dephosphorylation have been shown to downregulate virus multiplication. Thus, the small molecule salubrinal has been reported to inhibit several PERK/eIF2αphosphatases ([@B63]) and be effective against HSV1 ([@B64]) and dengue virus infections (65; reviewed in reference [@B66]). Moreover, the inhibitor guanabenz (Wytensin), a drug used for a long time to treat hypertension, was shown to inhibit the GADD34/PPP1R15α-dependent PERK/eIF2α phosphatase specifically (67). Consistent with such action, we show here that treatment of influenza virus-infected cells with guanabenz results in partial inhibition of viral protein synthesis under conditions that do not affect general cellular protein synthesis ([Fig. 4E](#fig4){ref-type="fig"} and [F](#fig4){ref-type="fig"}).

The PERK-induced UPR as a potential new anti-influenza virus target. {#s1.5}
--------------------------------------------------------------------

Influenza virus infection leads to the activation of a number of cell signaling pathways, including those dependent on NF-κB, Raf/MEK/ERK, and phosphatidylinositol 3-kinase (PI3K)/Akt (reviewed in references [@B30] and [@B68] to [@B70]). Thus, the expression of some viral proteins leads to the phosphorylation of IκB and the subsequent activation of NF-κB ([@B71]), which participates in the cellular innate and inflammatory responses. However, inhibition of this pathway has been shown to interfere with virus replication ([@B72]), probably because of a defect in caspase-3 activity and the subsequent retention of progeny RNPs in the nucleus (reviewed in reference [@B68]). Similarly, activation of the Raf/MEK/ERK pathway appears to be important for late events in the virus replication cycle, since its inhibition also leads to the accumulation of progeny RNPs in the nucleus. In this case, an ERK-dependent phosphorylation event in the viral NP or cellular factors seems to fire RNP export as a result of the late accumulation of viral hemagglutinin at the cell surface ([@B29], [@B73]). On the other hand, activation of the PI3K/Akt pathway by virus infection is bimodal. While an early burst of PI3K activation is induced by virus binding and is important for virus entry ([@B74]), late stimulation was also observed, which is relevant to avoid the premature appearance of apoptosis and is induced by the viral NS1 protein ([@B26], [@B27], [@B75], [@B76]). Thus, the virus makes use of cellular pathways that normally participate in the cellular innate and inflammatory responses to stimulate specific events in its replication cycle.

Contrary to these findings, here we show that influenza virus infection leads to attenuation of the PERK-mediated UPR ([Fig. 5A](#fig5){ref-type="fig"} to [C](#fig5){ref-type="fig"}) but does not induce general downregulation of the ATF6 or IRE1 arm of this stress response (see [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material). This is in contrast to previous studies showing the stimulation of ATF6- and IRE1-dependent UPR in virus-infected cells ([@B77], [@B78]). However, those investigators analyzed UPR activation at very late times after infection (12 to 48 h), long after the virus infection cycle is finished (around 8 h). Here, we show clear downregulation of PERK phosphorylation as early as 6 h after virus infection ([Fig. 6B](#fig6){ref-type="fig"} and [C](#fig6){ref-type="fig"}). This observation is in line with the activation in influenza virus-infected cells of p58^IPK^, a cellular inhibitor of PKR that also inhibits PERK autophosphorylation ([@B79]), although our data indicate a small transcriptional downregulation upon influenza virus infection (see [Table S1](#tabS1){ref-type="supplementary-material"}). In addition, upregulation of the transcription of GADD34/PPP1R15α, a coactivator of PERK/eIF2α phosphatase, was observed in virus-infected cells (see [Table S3](#tabS3){ref-type="supplementary-material"}), which could also account for the reduced levels of PERK phosphorylation ([Fig. 6A](#fig6){ref-type="fig"} to [C](#fig6){ref-type="fig"}).

Interestingly, these findings were derived from data obtained after the treatment of infected cells with MK, a known drug that has long been used for the treatment of asthma in humans (reviewed in reference [@B80]). When used at higher doses in influenza virus-infected human cells, MK preferentially reduced viral protein synthesis and accumulation ([Fig. 2](#fig2){ref-type="fig"} and [4](#fig4){ref-type="fig"}) without altering virus transcription or splicing ([Fig. 3](#fig3){ref-type="fig"}; see [Fig. S3](#figS3){ref-type="supplementary-material"} in the supplemental material). These findings are consistent with the stimulation of PERK phosphorylation observed upon MK treatment of mock-infected cells and the reversal of the virus-induced downregulation of PERK phosphorylation ([Fig. 6B](#fig6){ref-type="fig"} and [C](#fig6){ref-type="fig"}). Consistently, transcription of GADD34/PPP1R15α was not enhanced in virus-infected cells by treatment with MK (see [Table S3](#tabS3){ref-type="supplementary-material"} in the supplemental material).

The mechanism by which MK elicits activation of the PERK-mediated UPR but not the ATF6- and IRE1-dependent arms is not clear at this time. Treatment with MK does not downregulate the GADD34/PPP1R15α regulatory cofactor, but it is able to counteract virus-induced GADD34/PPP1R15α overexpression (see [Table S3](#tabS3){ref-type="supplementary-material"}). Anyway, the use of MK in influenza virus-infected cells has uncovered the PERK-mediated UPR as a potential target for anti-influenza virus treatment, which would complement the various virus targets presently under development. In addition, being a cellular target, it may eventually be useful for inhibiting other fast-replicating RNA viruses.

MATERIALS AND METHODS {#h2}
=====================

Biological materials. {#s2.1}
---------------------

The HEK 293T cell line ([@B81]) was obtained from J. C. de la Torre, the A549 human cell line ([@B82]) was obtained from J. A. Melero, and the Huh7 cell line ([@B83]) was obtained from P. Gastaminza. The MDCK cell line was purchased from the ATCC. Cell culture was carried out as previously described ([@B84]). Influenza virus strains A/Wisconsin/33 (H1N1) (WSN) and A/New Caledonia/20/99 (H1N1) and a recombinant virus containing the M, HA, and NA segments of WSN in the background of A/Victoria/3/75 (H3N2) (VIC) ([@B85]) were used in these experiments. Titrations were done in MDCK cells as previously described ([@B86]). VSV was provided by R. Alfonso and titrated in BHK21 cells. Plasmids pCMVPB1, pCMVPB2, pCMVPA, and pCMVNP, expressing the influenza virus polymerase subunits and the NP, have been previously described ([@B85]). Plasmid pHHclone23, a genomic plasmid expressing a deleted NS RNA segment (clone 23) ([@B57]) in negative polarity, was provided by R. Coloma. Antiserum specific for NP was generated by immunization of rabbits with recombinant NP ([@B57]). A polyclonal antibody specific for P-PERK (SC-32577) was purchased from Santa Cruz, and a monoclonal antibody specific for actin (ab8226) was purchased from Abcam. The secondary antibodies used for Western blotting were purchased from Sigma.

Plasmid construction. {#s2.2}
---------------------

To construct plasmid pHHGFP, a PCR fragment containing the gene for enhanced GFP flanked by the conserved sequences of the NS segment was amplified by using as primers 5′ TCAATCA*CGTCTC*TTATT[AGTAGAAACAAGGGTGTTTT]{.ul} 3′ and 5′ CAGTATCA*CGTCTC*TGGG[AGCAAAAGCAGGGTGACAAAG]{.ul} 3′, which contain the NS-specific sequences (underlined) and BsmBI restriction sites (italics). The PCR fragment was digested with BsmBI and ligated with BsmBI-digested plasmid pHH21 ([@B87]).

Chemical compounds. {#s2.3}
-------------------

The chemical libraries containing 727 compounds that have been clinically tested for a wide variety of indications were obtained from the National Institutes of Health Clinical Collection (NCC-104, NCC-201). MK sodium and T-705 (favipiravir) were obtained from AKOS GmbH (AKOS015833416 and AKOS005166863, respectively), and GSK-2656157 was obtained from MedKoo (406230). Wytensin (guanabenz) was obtained from Sigma (G110). All compounds were dissolved in DMSO at a 10 mM final concentration.

Library screening. {#s2.4}
------------------

Cultures of HEK293T cells in 96-well plates were transfected with a mixture of plasmids expressing the polymerase subunits (pCMVPB1, 3 ng; pCMVPB2His, 1.5 ng; pCMVPA, 2.5 ng) and NP (pCMVNP, 120 ng) and a genomic plasmid expressing a viral RNA-like GFP-encoding gene (pHHEGFP, 120 ng) by the calcium phosphate technique ([@B88]). As a control, HEK293T cells were transfected with 12 ng of pCAGGsGFP. At 2 hpi, compound stock solutions were diluted to 50 µM in 100 µl of growth medium (DMEM--5% fetal bovine serum \[FBS\]) and this mixture was added to each well. The cells were incubated at 37°C for 5 days, after which images of each well were collected on a Leica DMI 6000B with an ORCA-R2 digital camera (Hamamatsu). Images were acquired with a 10× (0.30 numerical aperture) objective and a resolution of 1,344 by 1,024 pixels. Quantification of the fluorescent signal was performed with the ImageJ software. Compound toxicity was determined by evaluating the metabolic activity of the cell biomass by the MTT cell viability assay ([@B89]).

Infection assays. {#s2.5}
-----------------

Cells were infected with viruses at the multiplicity of infection (MOI) specified for each experiment. After 1 h, cells were washed with phosphate-buffered saline (PBS) and overlaid with growth medium (DMEM--5% FBS) including the corresponding amount of MK, thapsigargin, GSK-2656157, guanabenz, or DMSO. Supernatants were harvested and used for virus titration by plaque assay in MDCK cells, or cell extracts were prepared for protein analysis.

Protein analyses. {#s2.6}
-----------------

Protein samples were separated by SDS-polyacrylamide gel electrophoresis and transferred to Immobilon filters. Western blotting was carried out essentially as previously described ([@B90]). The membranes were saturated with 3% bovine serum albumin for 1 h and then incubated with the primary antibodies for 1 h at room temperature. For Western blotting of phosphorylated proteins, the membranes were saturated with 5% milk for 1 h and then incubated with the primary antibodies overnight at 4°C. The filters were washed with PBS containing 0.25% Tween 20 (Tris-buffered saline containing 0.25% Tween 20 for phosphorylated proteins) and incubated with the appropriate secondary antibody conjugated to horseradish peroxidase. After further washing as described above, the filters were developed by enhanced chemiluminescence. The procedures for protein labeling *in vivo* have been previously described ([@B91]). Cultures were washed, incubated for 1 h in a DMEM medium lacking methionine-cysteine, and labeled with \[^35^S\]methionine-cysteine to a final concentration of 50 µCi/ml. After incubation for 1 h, total extracts were prepared in Laemmli sample buffer and processed by polyacrylamide gel electrophoresis and autoradiography. For quantification of cell protein synthesis, the complete lanes were used, while quantification of viral protein synthesis was carried out with the specific protein bands indicated in the figures.

Transcription activity of viral RNPs. {#s2.7}
-------------------------------------

Recombinant RNPs containing the clone 23 genomic RNAs were generated and amplified in 8 × 10^6^ HEK293T cells by transfection of a mixture of plasmids expressing the polymerase subunits (pCMVPB1, 3 µg; pCMVPB2His, 3 µg; pCMVPA, 600 ng) and NP (pCMVNP, 12 µg) and a genomic plasmid (pHHclone23, 12 µg) by the calcium phosphate technique ([@B88]). At 24 h posttransfection, cell extracts were prepared and the enzymatic activity of viral RNPs was determined *in vitro* with β-globin mRNA as the primer donor as previously described ([@B57]).

RT-qPCR. {#s2.8}
--------

Quantification of primary transcription was carried out by reverse transcription-quantitative PCR (RT-qPCR) as described previously ([@B92]). A 5.5-µl mixture containing 200 ng of total RNA and 10 pmol of a tagged primer specific for NP mRNA (5′ CCAGATCGTTCGAGTCGTTTTTTTTTTTTTTTTTAATTGTCGTAC 3′) were heated for 10 min at 65°C, chilled immediately on ice for 5 min, and then heated again at 60°C. After 5 min, 14.5 µl of a preheated reaction mixture containing 4 µl of First-Strand Buffer (Invitrogen), 1 µl of 0.1 M dithiothreitol, 1 µl of a mixture of deoxynucleoside triphosphates (each at 10 mM), 1 µl of Superscript II reverse transcriptase (50 U/µl; Invitrogen), 1 µl of RNasin Plus RNase inhibitor (40 U/μl; Promega), and 6.5 µl of saturated trehalose was added and the mixture was incubated for 1 h. Real-time qPCR was performed with Power SYBR green PCR master mix (Applied Biosystems). Four microliters of a 10-fold dilution of the cDNA was added to a qPCR mixture containing 10 µl of SYBR green qPCR SuperMix, 1.5 µl of forward primer (10 µM), 1.5 µl of reverse primer (10 µM), and 3 µl of double-distilled water. The sequences of the primers specific for the NP mRNA are 5′ CCAGATCGTTCGAGTCGT 3′ and 5′ GTCGTGCCCTCTTTTGACAT 3′. The PCR was carried out in a PRISM 7000 sequence detection system (Applied Biosystems) with 1 cycle of 50°C for 2 min, followed by 1 cycle of 95°C for 10 min and 40 cycles of 95°C for 15 s and 60°C for 1 min. The cycle threshold was determined with the SDS analytical software (Applied Biosystems).

RNA purification, cDNA synthesis, and deep sequencing. {#s2.9}
------------------------------------------------------

For RNA extraction, cell pellets containing 2.5 × 10^6^ cells were resuspended in 1 ml of Trizol reagent (Invitrogen) and the RNA was purified as recommended by the manufacturer. The RNA was digested with RNase-free DNase (1 U/mg) for 1 h at 37°C, extracted with phenol-chloroform-isoamyl alcohol, and precipitated with ethanol. The purified RNA was resuspended in nuclease-free water, and the absorbance at 260 nm was measured (NanoDrop ND-1000). For deep sequencing, rRNA was removed with the Ribo-Zero rRNA removal kit (catalog no. RZH1046; Illumina). Each RNA preparation was monitored with an Agilent 2100 Bioanalyzer (Agilent Technologies). cDNA was synthesized with reverse transcriptase (SuperScript II, catalog no. 18064-014; Invitrogen) and random primers. The second strand of the cDNA incorporated dUTP instead of dTTP. Double-stranded DNA was subjected to A tailing and ligation of the bar-coded TruSeq adapters. Purification steps were done with AMPure XP beads. Library amplification was performed by PCR with the primer cocktail supplied in the kit. Final libraries were analyzed with Agilent DNA 1000 chips to estimate the quantity and check size distribution and were then quantified by qPCR with the KAPA Library Quantification kit (catalog no. KK4835; KAPA Biosystems) prior to amplification with Illumina cBot. Sequencing was done with Illumina HiSeq by using single reads of 50 nt.

Transcriptome sequencing (RNA-Seq) data analysis. {#s2.10}
-------------------------------------------------

The quality of Illumina reads (50 nt) was checked with FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). No additional read filtering was needed. TopHat2 ([@B93]) was used to align all reads against a human (GRCh38) or influenza virus (A/Victoria/3/75 \[H3N2\]) genome. The htseq-count function of the HTSeq package ([@B94]) was used to assign read counts with all of the human genes (GRCh38 Ensemble release 76). The DESeq2 package ([@B95]) of the bioconductor project (<http://www.bioconductor.org>) was used to determine the statistical significance of the differential expression of genes, and the results are presented as adjusted *P* values ([@B96]) based on two biological replicates per sample. Detection of outliers based on Cook's distance was disabled (cooksCutoff = FALSE). FIESTA viewer ([@B97]) was used for real-time graphic evaluation of the application of different combinations of fold changes and FDR thresholds for filtering of gene expression results.

Nucleotide sequence accession number. {#s2.11}
-------------------------------------

The RNA-Seq data obtained in this study have been deposited in the Gene Expression Omnibus database under accession no. GSE68673.

SUPPLEMENTAL MATERIAL {#sm1}
=====================

###### 

Screening parameters. The average values determined for 96 GFP-positive wells (μ~pos~), negative wells (μ~neg~), and the corresponding standard deviations (δ~pos~ and δ~neg~) are shown. These values were used to calculate the reproducibility (Z), percent coefficient of variation (%CV), signal-to-background (S/B) ratio, and signal-to-noise (S/N) ratio with the formulas shown. Download

###### 

Figure S1, PDF file, 0.1 MB

###### 

Characterization of the MK preparation used for screening. (A) Chemical structure of MK obtained from the PubChem database (CID 23663996) corresponding to the formula C~35~H~35~ClNNaO~3~S and a molecular mass of 608.16 g/mol. The mass spectra of samples of the compound MK obtained from the NIH library (B) and AKOS GmbH (C), as determined by matrix-assisted laser desorption ionization\--time of flight tandem mass spectrometry, are shown. Peaks correspond to ionized fragments of the compound generated by laser irradiation and separated by mass/charge ratios with a mass spectrometer. Download
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Figure S2, PDF file, 0.5 MB

###### 

Splicing of influenza virus mRNA is not altered by MK treatment. Cultures of human A549 cells were infected with influenza virus at an MOI of 3 PFU/cell and then treated with 20 µM MK or the corresponding amount of DMSO. Total cell RNA was isolated at 6 hpi, and rRNA was removed. Viral RNA of each segment was determined by deep sequencing and classified according to the virus segment and polarity. The splicing efficiencies of segments 7 (M2/total M) and 8 (NEP/total NS) are presented as reads in splice junctions versus the total reads in each segment mRNA. Download
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Figure S3, PDF file, 0.2 MB

###### 

Functional protein association network of the genes differentially expressed in influenza virus-infected cells upon treatment with MK. Shown is the protein-protein interaction network as visualized by the STRING database. The nodes represent proteins, red circles contain most of the proteins differentially expressed in influenza virus-infected cells upon treatment with MK, and the lines represent the predicted functional associations. The associations were inferred from several types of evidence from the STRING database: the presence of experimental evidence (pink line), text mining evidence from abstracts of the scientific literature (yellow line), information from databases (light blue), sequence homology (light gray), co-occurrence evidence (dark blue), and coexpression evidence (dark gray). Retrieved from STRING 9.1, 2015. Download
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Figure S4, PDF file, 0.2 MB

###### 

MK inhibits viral protein synthesis. Cultures of human A549 cells were infected with the New Caledonia (H1N1) or VIC (H3N2) strain of influenza virus or with VSV at an MOI of 3 PFU/cell and then treated with 40 µM MK or the corresponding amount of DMSO. At 6 hpi, the cultures were pulse-labeled with \[^35^S\]methionine-cysteine and total protein extracts were prepared. (A) The samples were analyzed by polyacrylamide gel electrophoresis and autoradiography. The mobility of some of the virus-specific proteins (stars for influenza virus and arrows for VSV) is indicated to the right. (B) Quantification of the signals of DMSO-treated (blue) and MK-treated (red) samples. Download
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Figure S5, PDF file, 0.9 MB

###### 

Alterations of the ATF6- and IRE1-dependent unfolded protein response pathways by influenza virus infection (FLU) and/or MK treatment. Shown are the genes regulated by the transcription factors ATF6 and IRE1. The identification (ID) code in the Ensembl database is specified, as well as the FC and the FDR.
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Table S1, PDF file, 0.1 MB

###### 

Lack of alteration of genes downregulated by virus infection upon MK treatment. Shown are the genes downregulated by influenza virus infection (FLU versus MOCK; cutoff values, FC of less than −3 and FDR of \<10^−3^) and the lack of their modification by treatment with MK (FLU-MK versus FLU, MOCK-MK versus MOCK). The identification (ID) code in the Ensembl database is specified, as well as the FC and the FDR.
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Table S2, PDF file, 0.1 MB

###### 

Alterations of GADD34/PPP1R15α transcription by influenza virus infection (FLU) and/or MK treatment. The identification (ID) code in the Ensembl database is specified, as well as the FC and the FDR.
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Table S3, PDF file, 0.1 MB
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